Loading
Life sciences · Journal article
Pharmacognosy Magazine · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Type 2 diabetes (T2D) remains a prominent chronic metabolic disease characterized by hyperglycemia worldwide. Insulin resistance is the primary risk factor contributing to T2D development. Cornus mas L. is a natural product shown to play a regulatory role in metabolic disorders. Purpose This study aimed to explore the effects of Cornus mas L. on hepatic insulin resistance in high-fat diet-induced diabetic mice. Materials and Methods In this study, C57BL/6J mice were first fed a high-fat diet (HFD) for 12 weeks to establish an obesity model. Subsequently, the mice were orally administered an aqueous extract of C. mas L. at two dosages (500 and 1,000 mg/kg body weight/day) for 8 weeks to evaluate its therapeutic effects. Results The results demonstrated that C. mas L. supplementation reduced serum and hepatic glucose and lipid levels and improved glucose tolerance and insulin sensitivity. Moreover, C. mas L. supplementation promoted fatty acid oxidation genes (CPT1α and LCAD) and inhibited the expression of the glycogen synthesis gene GSK3β, as well as the expression of genes related to lipid synthesis and gluconeogenesis (ACC1, FAS, G6Pase, PEPCK, and FoxO1) at the mRNA level in the liver. Conclusion Therefore, our findings indicated that C. mas L. ameliorates hepatic insulin resistance in HFD-induced T2D mice by regulating the transcriptional level of glucolipid metabolism-related genes, suggesting that the protective effects of C. mas L. could serve as a novel strategy for the treatment of T2D.